Senator Criticizes Limits On Sales Of Genentech’s Avastin

Genentech’s plan to limit the availability of cancer drug Avastin, which would require physicians to use a more expensive version of the drug called Lucentis to treat wet age-related macular degeneration, will cost taxpayers $1 billion to $3 billion annually, according to Sen. Herb Kohl (D-Wis.), [click link for full article]

More: continued here

Filed under: Eye Health on December 2nd, 2007